Roanna Ruiz
Stock Analyst at Leerink Partners
(0.57)
# 3,754
Out of 4,829 analysts
63
Total ratings
28.57%
Success rate
-24.83%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.40 | +191.67% | 1 | Apr 28, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $4.95 | +21.21% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $11.53 | +56.11% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.69 | +45.07% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.48 | +265.30% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $13.39 | +101.64% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $2.87 | +352.96% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $3.56 | +293.26% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $312.18 | +5.71% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $32.94 | +76.10% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $71.77 | -65.17% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $5.64 | +768.79% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $2.45 | +430.61% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.98 | +101.34% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $19.19 | -0.99% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $80.19 | +49.64% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $5.50 | +809.09% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $10.64 | +276.12% | 6 | Oct 19, 2022 |
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.40
Upside: +191.67%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.95
Upside: +21.21%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $11.53
Upside: +56.11%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.69
Upside: +45.07%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.48
Upside: +265.30%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $13.39
Upside: +101.64%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $2.87
Upside: +352.96%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $3.56
Upside: +293.26%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $312.18
Upside: +5.71%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $32.94
Upside: +76.10%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $71.77
Upside: -65.17%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $5.64
Upside: +768.79%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $2.45
Upside: +430.61%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.98
Upside: +101.34%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $19.19
Upside: -0.99%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $80.19
Upside: +49.64%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $5.50
Upside: +809.09%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $10.64
Upside: +276.12%